Anavex Life Sciences Corp (AVXL)

[Investor2014]

It may be possible that the baseline cognitive score being on the better side means more good days for placebo patients than otherwise because they think or feel they are getting A2-73 when they are not.

For the actual genetic and fluid based biomarkers I doubt they would predisposition patients differently in terms of possible response to placebo, but they would influence outcomes once that patient actually receives A2-73 during OLE just as is expected if on A2-73 during the trial.